Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Alpha-fetoprotein (AFP) accounted for 1/3 of the total plasma protein in the fetus at 13 weeks, reached the highest peak at 30 weeks of gestation, and then gradually decreased. The plasma concentration at birth was about 1% of the peak period: about 40 mg / L, close to the adult level (less than 20 μg / L) at the age of one year. When hepatocytes regenerate after cancer or injury, the function of producing AFP is restored. As the condition worsens, the level of AFP in serum will rise sharply. In addition, there are different degrees of elevation of AFP in pregnancy, some gastrointestinal tumors, acute and chronic liver diseases. With the deepening of its research, the application value of AFP in various diseases is gradually reflected.
Tahtouh et al. showed that the inhibition of telomerase, PKC and PI3K/Akt/mTOR/STAT3 signaling pathways resulted in decreased AFP expression and secretion. In contrast, inhibition of the MAPK/ERK pathway did not show any effect. Telomerase regulation of AFP may be through the PI3K/Akt/mTOR/STAT3 signaling pathway or through an independent pathway. Further research is needed to elucidate the regulation of telomerase on AFP.
Figure 1. Schematic representation of intracellular signaling pathways leading to AFP expression and secretion. (Tahtouh, et al. 2015)
Diagnostic Value of AFP
AFP is currently the most commonly used method for diagnosing liver cancer and the most important tumor index. The diagnostic criteria are AFP ≥ 400 μg/L. This can exclude chronic or active hepatitis, cirrhosis, testicular or ovarian embryogenic tumors, and pregnancy. About 60% to 70% of patients with liver cancer have elevated AFP, of which about 18% of patients with liver cancer have low AFP levels, and about 30% of patients with liver cancer have normal AFP levels.
Hepatitis B virus (HBV) and/or Hepatitis C virus (HCV) infection, long-term alcohol abuse, non-alcoholic steatohepatitis, food contaminated with aflatoxin, and the men have the family history of liver cirrhosis and liver cancer, especially in men over 40 years old, is defined as a high-risk group of liver cancer. It is recommended to conduct a screening test at least every 6 months with B-ultrasound. AFP plays an important role in evaluating the efficacy of various treatments for liver cancer. The criteria for the radical resection of liver cancer require no tumor lesions were found. If the preoperative AFP is elevated, AFP is required 2 months’ quantitative determination after surgery until the level of AFP is in the normal range (very few patients have AFP down to normal for more than 2 months). After liver transplantation, TACE, radiofrequency ablation of liver cancer, targeted therapy, and radiotherapy and chemotherapy, continuous increase in serum AFP levels often suggests a poor prognosis.
Combined Detection of AFP, AFP⁃L3, and Abnormal Prothrombin (DCP)
AFP ⁃L is a glycoprotein which can be divided into three types according to its affinity with lentil lectin (LCA) on affinity electrophoresis, namely AFP⁃L1, AFP⁃L2 and AFP⁃L3. AFP⁃L3 is mainly derived from liver cancer cells, which makes it closely related to liver cancer. Related studies have shown that high levels of AFP⁃L3 before treatment indicate a poor prognosis for primary liver cancer (PHC). In recent years, AFP⁃L3 has been used as an important marker to detect PHC and is widely used in clinical practice.
LIM et al. selected 361 patients with hepatocellular carcinoma as the study object, and analyzed the data by detecting the levels of AFP, AFP⁃L3 and DCP in the serum to diagnose PHC. When AFP, AFP⁃L3, and DCP are combined, the diagnostic accuracy is significantly better than their separate detection. CHOI et al. selected 90 patients with hepatocellular carcinoma and found that the combined detection of AFP⁃ L3 and DCP is up to 90% sensitive for those with early, single, small, and low-concentration AFP. This is important for clinically improving the accuracy of PHC diagnosis.
BEST et al. selected 285 patients with hepatocellular carcinoma and found that the combined detection of AFP, AFP, L3, and DCP has the highest sensitivity compared with the single test, suggesting the significance for early AFP-negative hepatocellular carcinoma.
Joint Detection of AFP, DCP, DKK1
DKK1 is a secreted inhibitory factor and is closely related to Wnt signaling pathway. FOUAD et al. found that DKK1 may be a key regulator of hepatocellular carcinoma progression and a potential target for the treatment of liver cancer. ERDAL and other studies have found that the combined detection of DKK1 and AFP for the diagnosis of hepatocellular carcinoma is superior to the separate detection.
Eighty-six patients with liver cancer were selected as their own subjects, and their AFP, DCP, and DKK1 levels were measured. The data were analyzed to obtain AFP, DCP, and DKK1 with sensitivity of 58.13%, 74.42%, and specificity of 73.26%. 29.00%, 30.00%, and 44.00%, the sensitivity and specificity of the combined detection were 93.02% and 78.00%, respectively. This study demonstrates that AFP, DCP, and DKK1 combined with hepatocellular carcinoma have higher sensitivity and specificity than those of the single test, which is important for clinical diagnosis of hepatocellular carcinoma.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.